nd time-dependent manner and were maintained for at least 72 hours after infusion of CSL112 at 40 mg/kg and higher. Notable biomarker changes included elevations in PreBeta1-HDL (maximum=3,600%) and global cholesterol efflux capacity from macrophages (maximum=270%).
In another study presented at the meeting, CSL112 was observed to have strong anti-inflammatory properties in human blood ex vivo. This property of CSL112 may prove to be beneficial in the reduction of inflammation associated with cardiovascular events.
"We are very encouraged by the early experience with CSL112 in the clinic and are looking forward to completing the mid-stage studies that are now in progress or being planned to start next year," said Chuck Shear, CSL Senior Director and Therapeutic Area Head.
CSL112 is a novel formulation of apolipoprotein A-I (ApoA-I), the chief component of high-density lipoprotein (HDL). It is purified from plasma and reconstituted to form HDL suitable for intravenous infusion. As demonstrated in pre-clinical and Phase 1 studies, CSL112 elevates cholesterol efflux capacity, as well as additional steps in reverse cholesterol transport. CSL112 demonstrates strong anti-inflammatory activity, as well.
Headquartered in Melbourne, Australia, CSL Limited is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the United States, and employs over 11,000 people in more than 25 countries. Visit www.csl.com.au for more information.
Sheila A. Burke
Director, Communications & Public Relations
Worldwide Commercial Operations
C: 484-919-2618 (US)
Sheila.Burke at cslbehring.com
Eliot HarrisonPage: 1 2 3 4 Related medicine technology :1
MCS Healthcare Public Relations
. Novelos Therapeutics Closes $2 Million Private Placement2
. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer3
. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz4
. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center5
. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies6
. Frost & Sullivan Lauds IncellDx for Developing a Novel, Non-invasive Method for Cervical Cancer Testing7
. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic8
. MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market9
. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress10
. Strategic Agreement Launches Novel Drug Development Model11
. Kalidex Introduces Novel Fluoroquinolone, KPI-10, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)